Jeevan Scientific Technology Ltd (JSTL) is currently trading at 87.99 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Jeevan Scientific Technology Limited is an India-based independent clinical contract research organization providing integrated clinical research services, bioanalytical laboratory testing, BA/BE studies and Phase I–IV clinical trial support, operating a 132-bed clinical pharmacology unit and bioanalytical facilities under the parent and its subsidiary Nayas Laboratories. In H1 FY2026 the consolidated revenue was Rs. 2,117.86 lakhs while consolidated loss before tax was Rs. 369.90 lakhs, reflecting elevated operating cost, higher depreciation and modest revenue growth; standalone H1 revenue was Rs. 1,864.74 lakhs with a standalone loss before tax of Rs. 268.56 lakhs, indicating margin pressure across the group. The company continues to invest in fixed assets and capacity: standalone PPE purchases were ~Rs. 438.85 lakhs in H1 and consolidated CWIP stands at Rs. 471.05 lakhs, showing deliberate capex to increase throughput for clinical pharmacology and bioanalytical services and to meet regulatory client demand. Operationally, Jeevan Scientific’s differentiator is integrated end-to-end clinical research capability supported by MHRA-inspected facilities, multiple LC-MS/MS systems and a recently consolidated subsidiary, enabling cross-selling to global pharmaceutical and biotech clients while still navigating working capital and profitability recovery.

Over the past 52 weeks, Jeevan Scientific Technology Ltd has traded between a low of ₹57.15 and a high of ₹93.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Jeevan Scientific Technology Ltd has a market capitalization of approximately 178.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Jeevan Scientific Technology Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 22.24 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 178.13 Cr, Jeevan Scientific Technology Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Jeevan Scientific Technology Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Jeevan Scientific Technology Ltd is 22.24. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Jeevan Scientific reported Rs 16.48 crore of consolidated purchases of fixed assets for the half year ended 30 September 2026. The cash-flow statement included this amount within investing activities, which had a net outflow of Rs 16.45 crore.

Jeevan Scientific reported consolidated profit after tax of Rs 2.82 crore for the quarter ended 30 September 2026. This compared with Rs 3.08 lakh in the year-earlier quarter and Rs 54.48 lakh in the preceding June 2026 quarter.

JSTL reported revenue from operations of ₹18.3 crore for Q1 FY27, according to the company-specific quarterly results update. That figure represented year-on-year growth of 81.2%.